CancerDrs

Breast Cancer clinical trials in West Virginia

6 actively recruiting breast cancer trials at 7 sites across West Virginia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in West Virginia:
  • United Hospital Center — Bridgeport, West Virginia
  • WVUH-Berkely Medical Center — Martinsburg, West Virginia
  • West Virginia University Healthcare — Morgantown, West Virginia
  • Camden Clark Medical Center — Parkersburg, West Virginia
  • Princeton Community Hospital — Princeton, West Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in West Virginia:
  • United Hospital Center — Bridgeport, West Virginia
  • WVUH-Berkely Medical Center — Martinsburg, West Virginia
  • West Virginia University Healthcare — Morgantown, West Virginia
  • Camden Clark Medical Center — Parkersburg, West Virginia
  • Princeton Community Hospital — Princeton, West Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in West Virginia:
  • United Hospital Center — Bridgeport, West Virginia
  • Edwards Comprehensive Cancer Center — Huntington, West Virginia
  • West Virginia University Healthcare — Morgantown, West Virginia
  • Camden Clark Medical Center — Parkersburg, West Virginia
  • Princeton Community Hospital — Princeton, West Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in West Virginia:
  • Edwards Comprehensive Cancer Center — Huntington, West Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in West Virginia:
  • WVUH-Berkely Medical Center — Martinsburg, West Virginia
  • West Virginia University Healthcare — Morgantown, West Virginia
  • Camden Clark Medical Center — Parkersburg, West Virginia
  • Wheeling Hospital/Schiffler Cancer Center — Wheeling, West Virginia
View on ClinicalTrials.gov →
NA Recruiting Industry

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk…

Sponsor: Natera, Inc.
NCT ID: NCT07214532
Sites in West Virginia:
  • West Virginia University — Morgantown, West Virginia
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19